Medtronic, Farapulse Advance Pulsed Field Ablation With US Trials
Executive Summary
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
You may also be interested in...
Cardio Catch-Up: Trial Of Biosense Webster’s Dual-Energy Ablation System Finishes Enrollment
On 19 July, Biosense Webster announced the final enrollment in the SmartfIRE trial of its Thermocool Smarttouch SF cardiac ablation catheter with the Trupulse generator and Carto imaging system.
JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.
Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story
Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.